Ensign Peak Advisors, Inc Gossamer Bio, Inc. Transaction History

Ensign Peak Advisors, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.98 - $1.53 $1.07 Million - $1.67 Million	1,092,924 Added 753.35%	1,238,000 $1.49 Million
Q4 2022 Feb 13, 2023	SELL	$1.74 - $12.87 $35,739 - $264,349	-20,540 Reduced 12.4%	145,076 $314,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $32,517 - $67,108	4,510 Added 2.8%	165,616 $1.98 Million
Q2 2022 Aug 12, 2022	BUY	$5.97 - $9.97 $59,341 - $99,101	9,940 Added 6.58%	161,106 $1.35 Million
Q4 2021 Feb 11, 2022	BUY	$10.12 - $14.07 $61,630 - $85,686	6,090 Added 4.2%	151,166 $1.71 Million
Q1 2021 May 12, 2021	SELL	$8.63 - $10.94 $323,374 - $409,932	-37,471 Reduced 20.53%	145,076 $1.34 Million
Q3 2020 Nov 12, 2020	SELL	$11.3 - $14.75 $138,775 - $181,144	-12,281 Reduced 6.3%	182,547 $2.27 Million
Q2 2020 Aug 12, 2020	SELL	$9.52 - $15.98 $116,496 - $195,547	-12,237 Reduced 5.91%	194,828 $2.53 Million
Q1 2020 May 11, 2020	SELL	$8.0 - $15.48 $377,952 - $731,337	-47,244 Reduced 18.58%	207,065 $2.1 Million
Q4 2019 Feb 14, 2020	BUY	$14.82 - $26.79 $3.77 Million - $6.81 Million	254,309 New	254,309 $3.98 Million

108

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $90.2M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.